RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
7.95
-0.21 (-2.57%)
At close: Nov 4, 2024, 4:00 PM
8.18
+0.23 (2.89%)
After-hours: Nov 4, 2024, 4:32 PM EST
RedHill Biopharma Employees
RedHill Biopharma had 53 employees as of December 31, 2023. The number of employees decreased by 60 or -53.10% compared to the previous year.
Employees
53
Change (1Y)
-60
Growth (1Y)
-53.10%
Revenue / Employee
$69,943
Profits / Employee
-$569,321
Market Cap
10.18M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
PAVmed | 107 |
Mustang Bio | 80 |
Jaguar Health | 49 |
Senti Biosciences | 48 |
Brainstorm Cell Therapeutics | 29 |
Dominari Holdings | 28 |
Edesa Biotech | 16 |
Kiora Pharmaceuticals | 12 |
RDHL News
- 7 days ago - RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND - PRNewsWire
- 13 days ago - RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury - PRNewsWire
- 21 days ago - RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment - PRNewsWire
- 4 weeks ago - RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians - PRNewsWire
- 5 weeks ago - RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041 - PRNewsWire
- 2 months ago - RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines - PRNewsWire
- 2 months ago - RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire
- 2 months ago - New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality - PRNewsWire